Acambis retains neutral rating from Merrill

Merrill Lynch analyst Erica Whittaker kept Acambis at a neutral rating after the company reported third-quarter 2006 financial results with a greater one-off profit than the analyst had forecast. While revenues missed Whittaker's estimate, profit was higher, due to much lower research and development expenses. Acambis retained its revenue outlook for the year of £30 million. Shares of the Cambridge, England-based pharmaceutical company were up 5.00p, or 3.23%, at 160.00p. (London: ACM)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.